MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

CureVac NV

Closed

2.86 4.76

Overview

Share price change

24h

Current

Min

2.7

Max

2.86

Key metrics

By Trading Economics

Income

443M

371M

Sales

479M

494M

P/E

Sector Avg

5.431

63.778

EPS

1.5

Profit margin

75.029

Employees

999

EBITDA

441M

375M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+240.07% upside

Dividends

By Dow Jones

Next Earnings

23 kwi 2025

Market Stats

By TradingEconomics

Market Cap

664M

Previous open

-1.9

Previous close

2.86

Technical Score

By Trading Central

Confidence

Bullish Evidence

CureVac NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lip 2024, 09:14 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 lip 2024, 14:18 UTC

Acquisitions, Mergers, Takeovers

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 lip 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Peer Comparison

Price change

CureVac NV Forecast

Price Target

By TipRanks

240.07% upside

12 Months Forecast

Average 9.25 USD  240.07%

High 16 USD

Low 2.5 USD

Based on 3 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

1

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

2.72 / 2.905Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.